According to the latest financial report of Intra-Cellular Therapies, the latest earnings per share (TTM) for the company is -0.25. Investing in companies with strong earnings per share can potentially provide higher returns.
Interested in knowing about Intra-Cellular Therapies's free cash flow? The latest report shows it as -27.22M. Keep an eye on and closely monitor the company's cash flow to make informed investment decisions.
If you are evaluating a company's liquidity, current ratio is an important measure to consider. The latest financial report of Intra-Cellular Therapies shows that the company's current ratio is 7.66, indicating healthy liquidity.
Another liquidity indicator to closely monitor is quick ratio. According to the latest financial results of Intra-Cellular Therapies, the quick ratio is 6.94, indicating that the company can meet its short-term debt obligations.
Want to learn more about the financial health of Intra-Cellular Therapies? The latest ROE figure is -2.30%, indicating that the company has stable profitability.
Investors looking for profitability indicators may be interested in ROA. According to the latest financial results of Intra-Cellular Therapies, the total asset return on investment (ROA) is -1.99%.
Gross margin can provide insight into a company's pricing strategy and cost structure. Check Intra-Cellular Therapies's latest financial report to see how their gross margin is doing - currently at 91.26%.
For investors focusing on operational efficiency, net profit margin is an important indicator. According to the latest financial results of Intra-Cellular Therapies, the net profit margin is -15.01%, which is a good sign for its profitability.